Seven wonders of the CAR-T world

The landscape of cancer immunotherapy has been revolutionized by the emergence of chimeric antigen receptor T-cell (CAR-T) therapy, representing one of the most significant advances in oncology treatment over the past decade. Since the first FDA approval in 2017, seven CAR-T therapies have successfully navigated the regulatory pathway. Here, we examine each approved CAR-T therapy, highlighting the technical innovations, manufacturing approaches, and strategic considerations that have shaped this rapidly evolving field. Kymriah (tisagenlecleucel, tisa-cel) Manufacturer: Novartis (Basel, Switzerland) First approved: August 2017 Approved for: B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients Diffuse large B-cell lymphoma (DLBCL)...